4/19
08:19 am
pmvp
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
4/12
08:05 am
pmvp
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $5.00 price target on the stock.
High
Report
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $5.00 price target on the stock.
3/27
08:21 am
pmvp
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors [Yahoo! Finance]
Low
Report
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors [Yahoo! Finance]
3/27
08:00 am
pmvp
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Low
Report
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
3/18
04:12 pm
pmvp
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer [Yahoo! Finance]
Medium
Report
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer [Yahoo! Finance]
3/18
04:01 pm
pmvp
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
Low
Report
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
3/7
08:00 am
pmvp
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
3/1
10:37 am
pmvp
PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results [Yahoo! Finance]
2/29
04:13 pm
pmvp
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights [Yahoo! Finance]
Low
Report
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights [Yahoo! Finance]
2/29
04:01 pm
pmvp
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
Low
Report
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
2/26
08:18 am
pmvp
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference [Yahoo! Finance]
Medium
Report
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference [Yahoo! Finance]
2/26
08:00 am
pmvp
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
Medium
Report
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference